Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thoracic Tumours Register (RTT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02941458
Recruitment Status : Recruiting
First Posted : October 21, 2016
Last Update Posted : April 4, 2019
Sponsor:
Information provided by (Responsible Party):
Spanish Lung Cancer Group

Brief Summary:
The GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.

Condition or disease
Thoracic Tumors

Detailed Description:

In Europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. Potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. However, the priorities should be to prevent lung cancer by implementing anti-smoking policies and controlling asbestos exposure throughout Europe, such as was recommended by the World Health Organization (WHO) in 2008.14 Other priorities are to reduce levels of residential radon in risk areas, and early diagnosis to improve the results of surgery, which is still the main curative treatment.

The variability in the diagnostic process, treatment and advocacy, as well as the anticipated increase in associated mortality in Spain in coming years, has stimulated the creation of an epidemiological, observational, multicenter study of cases of lung cancer and other thoracic tumors diagnosed and treated by medical personnel, including both thoracic surgeons and medical oncologists. Data from this study will be collected retrospectively and prospectively, so as to enable an extensive study of the epidemiological and therapeutic factors related to the disease.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 10000 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: Thoracic Tumours Register
Study Start Date : July 2016
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Group/Cohort
Non-small cell lung cancer
patients treated for a non small cell lung cancer
Small cell lung cancer
patients treated for a small cell lung cancer
Mesotelioma
patients treated for a mesotelioma
timic cancer
patients treated for a timic cancer
carcinoid cancer
patients treated for a carcinoid cancer



Primary Outcome Measures :
  1. Describe epidemiology characteristics of lung cancer and other thoracic tumors in Spanish people [ Time Frame: up to 10 years ]
    To know the epidemiology characteristics of lung cancer and other thoracic tumors in Spain, as well as clinical and histological data, diagnosis, treatments received, and prognostic factors



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients treated due to a thoracic tumour
Criteria

Inclusion Criteria:

  • Patients with thoracic disease, treated with an active treatment or not treated (only palliative care)

Exclusion Criteria:

  • Patients with other type of tumours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02941458


Contacts
Layout table for location contacts
Contact: Eva Pereira +34934302006 epereira@gecp.org

  Show 66 Study Locations
Sponsors and Collaborators
Spanish Lung Cancer Group
Investigators
Layout table for investigator information
Principal Investigator: Mariano Provencio, MD Hospital Puerta del Hierro

Additional Information:
Layout table for additonal information
Responsible Party: Spanish Lung Cancer Group
ClinicalTrials.gov Identifier: NCT02941458     History of Changes
Other Study ID Numbers: GECP 16/01_RTT
First Posted: October 21, 2016    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms